Pre-made Ravagalimab benchmark antibody ( Whole mAb, anti-CD40 therapeutic antibody, Anti-p50/Bp50/CDW40/TNFRSF5 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-471

Pre-Made Ravagalimab biosimilar, Whole mAb, Anti-CD40 Antibody: Anti-p50/Bp50/CDW40/TNFRSF5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ravagalimab (formerly ABBV 323), a CD40 antagonist biologic, is being developed by AbbVie, for the treatment of ulcerative colitis and Sjogren's syndrome.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-471-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Ravagalimab biosimilar, Whole mAb, Anti-CD40 Antibody: Anti-p50/Bp50/CDW40/TNFRSF5 therapeutic antibody
INN Name Ravagalimab
TargetCD40
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI Structure6pe7:HL/6pe8:HL:AB
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2017
Year Recommended2018
CompaniesAbbVie
Conditions Approvedna
Conditions ActiveUlcerative colitis;Sjogren's syndrome
Conditions DiscontinuedCrohn's disease
Development Techna